BTIG raised the firm’s price target on Masimo to $200 from $195 and keeps a Buy rating on the shares as part of a broader research note titled "Q1 MedTech Quarterly Preview". While dynamics are improving, "nobody is in the clear yet", with more inflation still being present, interest rates remaining elevated, and recessionary risk looming over the global economy, the analyst tells investors in a research note. The firm adds however that procedures and staffing appear to be improving, capital equipment demand remains healthy, and FX has become less of a headwind for most names under coverage, setting up improvement for margins in the second half of the year.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MASI:
- Masimo announce updated ESAIC guidelines recommend hemoglobin monitoring
- Masimo, Temple Health enter strategic collaboration
- Masimo announces findings of prospective study of Masimo PVi
- Masimo price target raised to $192 from $173 at Needham
- Masimo price target raised to $150 from $135 at Piper Sandler